Targeting Sphingosine-1-Phosphate in Hematologic Malignancies

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 11, Iss. 9, 2011-11 ,pp. : 794-798

Bentham Science Publishers

Access to resources Recommend Favorite

HEMATOLOGIC MALIGNANCIES

By  

Cancer Investigation, Vol. 25, Iss. 1, 2007-01 ,pp. : 33-47

Informa Healthcare

Access to resources Recommend Favorite

Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A

By Langenheim John   Chen Wen  

Breast Cancer Research and Treatment, Vol. 90, Iss. 3, 2005-04 ,pp. : 281-293

Springer Publishing Company

Access to resources Recommend Favorite

Editorial [Hot Topic: Therapeutic Targeting of the Sphingolipid “Biostat” in Hematologic Malignancies (Guest Editors: Thomas P. Loughran and Hong-Gang Wang)]

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 11, Iss. 9, 2011-11 ,pp. : 780-781

Bentham Science Publishers

Access to resources Recommend Favorite

Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies

By Karp Judith E   Lancet Jeffrey E  

Future Oncology, Vol. 1, Iss. 6, 2005-12 ,pp. : 719-731

Future Medicine

Access to resources Recommend Favorite